Sanofi earnings date
Sanofi (SNW2) Q3 2026 Earnings Report
DE:SNW2 Q3 2026 EPS Results
- Actual EPS
- EUR 1.80
- Consensus EPS
- EUR 1.41
- Beat/Miss
- Beat by +EUR 0.39
- One Year Ago EPS
- EUR 1.54
DE:SNW2 Q3 2026 Revenue Results
- Actual Revenue
- EUR 13.10B
- Expected Revenue
- EUR 13.81B
- Beat/Miss
- Missed by -EUR 709.00M
- YoY Revenue Growth
- +15.85%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/30/2026
- Time
- Before Open
- Conference Call
- Friday, October 30, 2026
Sanofi's next earnings date is estimated for January 28, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Sanofi reported robust Q3 revenue, earnings, margin, Dupixent, new-launch, and rare-disease growth, upgraded 2026 guidance, and outlined significant strategic, R&D, AI, and external-innovation initiatives. The main challenges were the need to rebuild a pipeline that lags peers, discontinued development programs, vaccine phasing and supply constraints, upcoming portfolio-related sales reductions, Dupixent loss-of-exclusivity planning, and several areas of financial and regulatory uncertainty. The positive operating performance and breadth of stated growth initiatives significantly outweighed the disclosed challenges.
Sanofi upgraded 2026 guidance, expecting sales to grow at a low teens percentage, which usually means a range of 13%-15%, and business EPS to grow at a mid-teen percentage, which usually means between 15% and 17%; vaccine sales are expected to be down by a low single-digit percentage for the full year, while capital gains are expected to be around EUR 250 million and the Regeneron development balance ending creates a BOI headwind of about EUR 500 million in H2 2026, evenly distributed between Q3 and Q4. For 2027, Sanofi is not providing formal guidance, but expects pricing to return to a slightly negative pricing contribution to global sales growth, legacy-portfolio transactions to reduce sales by around EUR 1.3 billion, and BOI to increase in absolute value and BOI margin despite the H1 2027 impact of the end of the R&D reimbursement; cost base growth is expected at a lower level than sales. Sanofi expects Dupixent revenue of EUR 25 billion by 2030 and total group revenue to be impacted moderately by Dupixent's LOE, with a priority on preserving earnings and cash flow.
- Strong Third-Quarter Revenue GrowthQ3 total sales reached EUR 14.4 billion, up 14.3% versus last year. Underlying group sales growth, excluding items considered more one-off in nature, was estimated at around 12%.
- 2026 Guidance UpgradedSanofi upgraded its 2026 guidance and now expects sales to grow at a low teens percentage, usually meaning 13%-15%, and business EPS to grow at a mid-teen percentage, usually meaning 15%-17%.
- Profitable Growth and Margin ExpansionGross margin improved by 2.1 percentage points, BOI increased by 19.7%, BOI margin expanded by 1.9 percentage points, and business EPS grew by 19.6% in Q3. Operating expenses were basically stable due to cost-discipline programs, including R&D prioritization.
- Dupixent Delivered Record Quarterly SalesDupixent sales reached EUR 5.7 billion in Q3, surpassing EUR 5 billion for the second consecutive quarter. Growth was driven primarily by increasing demand and favorable gross-to-net adjustments, with more than 1.5 million patients under treatment globally.
- Dupixent Maintained Market LeadershipIn the U.S., Dupixent remained the number one prescribed biologic among key prescriber groups. Outside the U.S., growth was driven primarily by market expansion across major indications in Germany, France, Japan, Canada, and China.
- Strong New-Launch MomentumPharma launches grew over 31% in Q3, driven mainly by ALTUVIIIO, Ayvakit, and Rezurock. Sales from the portfolio of newly launched medicines reached approximately EUR 2.2 billion, up 19.2%, and represented roughly 15% of total company sales.
- Rare-Disease Portfolio GrowthRare-disease sales reached EUR 1.9 billion, up 12.6%. Performance was supported by Ayvakit, continued ALTUVIIIO momentum, and recently launched medicines including Wayrilz, Cablivi, Qfitlia, Myqorzo, Anxu, and Redemplo.
- Resilient Vaccine PerformanceThe vaccines franchise declined 7% in Q3, better than the previously indicated low-to-mid-teens decline, due to more favorable buying patterns for Beyfortus late in the quarter. Heplisav-B grew 60% on a pro forma basis to EUR 125 million, and full-year vaccine sales are expected to decline by a low single-digit percentage.
- Clearer Strategic FocusSanofi confirmed immunology, rare diseases, and vaccines as its three focus areas, citing robust growth opportunities and potential for differentiation. The company intends to align R&D and external innovation capital primarily behind these areas.
- Expanded Regeneron AllianceSanofi expanded its alliance with Regeneron to gain access to four next-generation, long-acting monoclonal antibodies targeting type two inflammation. The lead anti-IL-13 program is already in phase I for atopic dermatitis, with potential dosing every three to six months, and registrational studies are expected to start in late 2027 or early 2028.
- Pipeline Replenishment and External InnovationThe company described the expanded Regeneron alliance as an important first step in replenishing its early-stage pipeline. Sanofi also plans to pursue business development and M&A, including late-stage and commercial medicines, disciplined bolt-on acquisitions, and innovation sourced globally, including from China.
- R&D Transformation and AI InvestmentSanofi plans to improve research-platform use, accelerate AI integration in drug discovery, expand external innovation access, use adaptive study designs, strengthen technical-review governance, and increase talent density. The company intends to deploy integrated AI agents company-wide and expand partnerships in this area.
- Pipeline Scale and Planned R&D OutputThe pipeline comprises 61 development projects across pharma and vaccines, including 36 new molecules. Sanofi aims to start 12-15 first-in-human studies each year while maintaining its quality standards and targeting a 50/50 internal/external sourcing split.
- Positive Regulatory and Development ProgressSanofi received the Ayvakit 50 mg U.S. label expansion in indolent systemic mastocytosis and EU approval for MenQuadfi in patients from six weeks of age. Teizeild was accepted for EU review in stage two Type 1 diabetes in children aged one to seven, while Beyfortus received priority review in China and SP0289 received EU PRIME designation.
- Promising Key Pipeline ProgramsManagement highlighted efdoralprin alfa as addressing an area with poor standard of care and potentially offering benefits in convenience and efficacy. Frexalimab is being explored in multiple sclerosis, Type 1 diabetes, and transplant, while duvakitug was described as having strong phase II efficacy in IBD and a potential subcutaneous development advantage.
- Strong Cash Flow and Capital Allocation CapacitySanofi said strong cash-flow generation, a strong balance sheet, low leverage, and access to external financing support disciplined BD and M&A while retaining a strong investment-grade credit rating. The company reaffirmed its dividend policy, including 31 consecutive years of dividend increases in absolute euro value.
- Long-Term Dupixent and Earnings ObjectivesManagement confirmed confidence in reaching EUR 25 billion of Dupixent sales by 2030 at constant exchange rates. Sanofi expects BOI to increase in absolute value and BOI margin each year from now through 2030, including in 2027 despite the end of the Regeneron R&D reimbursement.
DE:SNW2 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Jan 28, 2027 | 2026 (Q4) | 0.87- | 0.83 | ― | ― |
| Oct 30, 2026 | 2026 (Q3) | 1.411.80 | 1.54 | 17.08% (+0.26) | |
| Jul 30, 2026 | 2026 (Q2) | 0.991.09 | 0.83 | 32.09% (+0.27) | |
| Apr 23, 2026 | 2026 (Q1) | 0.941.00 | 0.71 | 40.25% (+0.29) | |
| Jan 29, 2026 | 2025 (Q4) | 0.770.83 | 0.62 | 33.67% (+0.21) | |
| Oct 24, 2025 | 2025 (Q3) | 1.441.54 | 1.41 | 9.23% (+0.13) | |
| Jul 31, 2025 | 2025 (Q2) | 0.870.83 | 0.85 | -3.09% (-0.03) | |
| Apr 24, 2025 | 2025 (Q1) | 0.850.71 | 0.87 | -17.63% (-0.15) | |
| Jan 30, 2025 | 2024 (Q4) | 0.640.62 | 0.82 | -24.03% (-0.20) | |
| Oct 25, 2024 | 2024 (Q3) | 1.231.41 | 1.23 | 14.83% (+0.18) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


